Lifelong Learning

COVID-19 Webinar Series

COVID-19 Webinar Series

The Office of Lifelong Learning is committed to providing the latest information during the COVID-19 pandemic and has developed a series of webinars for physicians and other healthcare providers.

The first three webinars can now be downloaded as recordings. Please follow the link to the right to gain access.

We anticipate offering further COVID-19 webinars soon. Please sign up for our newsletter to stay up to date our our latest COVID-19 educational offerings. 


Public Health Laboratory Response to COVID-19
Recording now available

Presented by Alberta Precision Laboratory – Public Health Laboratory team

  • Graham Tipples, Medical-Scientific Director
  • Nathan Zelyas, Medical Microbiologist, Program Leader for Respiratory Viruses
  • Kanti Pabbaraju, Scientist, Research and Rapid Response
  • Mark Douesnard, Clinical Supervisor
  • Natalie Marshall, Clinical Microbiology Fellow, University of Alberta Health Services

 

Learning Objectives

  • To understand the role of a public health laboratory in responding to emerging diseases
  • To describe the rapid development and validation of COVID-19 virus testing
  • To describe the operational aspects of increasing testing from low to very high volumes over a short period of time
  • To describe the partnerships and systems that have facilitated the rapid response to COVID-19 testing in Alberta
  • To describe the current situation and future plans for COVID-19 testing in Alberta
Download the recording

The Development and Prospects for Antivirals for COVID-19
Recording now available

Presented by Dr. D. Lorne Tyrrell

D. Lorne Tyrrell is a Distinguished University Professor at the University of Alberta.
He is the Founding Director of the Li Ka Shing Institute of Virology. He has focused
his research since 1986 on viral hepatitis. His work on the development of antiviral
therapy was supported by CIHR and Glaxo Canada. It resulted in the licensing of the
first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998.
Today, lamivudine is licensed in over 200 countries worldwide for the treatment of
HBV.

Download the recording

Prospects for a COVID-19 Vaccine
Recording now available.

Presented by Dr. Michael Houghton

Dr. Houghton is the Director of the Li Ka Shing Applied Virology Institute and a Professor in the Department of Medical Microbiology & Immunology at the UofA. He leads an experienced team that has been developing a vaccine against the hepatitis C virus and now intend to use the same technology to expedite a COVID-19 vaccine.

Download the recording